GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth
Executive Summary
GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.
You may also be interested in...
HBW US Market News: Awards, Appointments, Actions And Nutrition And Disaster Relief
Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.
Haleon’s EMEA Head Filippo Lanzi: There’s More To Innovation Than Rx-To-OTC Switch
Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment.
Haleon Starts Standalone Life By Raising Sales Expectations
A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.